Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4243017
Max Phase: Preclinical
Molecular Formula: C24H25N5O2
Molecular Weight: 415.50
Molecule Type: Small molecule
Associated Items:
ID: ALA4243017
Max Phase: Preclinical
Molecular Formula: C24H25N5O2
Molecular Weight: 415.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cn1ccc2c(Cc3ccc(-n4cccn4)cc3)cc(C(=O)NC3CCOCC3)nc21
Standard InChI: InChI=1S/C24H25N5O2/c1-28-12-7-21-18(15-17-3-5-20(6-4-17)29-11-2-10-25-29)16-22(27-23(21)28)24(30)26-19-8-13-31-14-9-19/h2-7,10-12,16,19H,8-9,13-15H2,1H3,(H,26,30)
Standard InChI Key: HDVXKQHNMHYAJS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 415.50 | Molecular Weight (Monoisotopic): 415.2008 | AlogP: 3.26 | #Rotatable Bonds: 5 |
Polar Surface Area: 73.97 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 1.82 | CX LogP: 3.04 | CX LogD: 3.04 |
Aromatic Rings: 4 | Heavy Atoms: 31 | QED Weighted: 0.54 | Np Likeness Score: -1.38 |
1. Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW.. (2018) VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events., 9 (9): [PMID:30258541] [10.1021/acsmedchemlett.8b00261] |
Source(1):